Context Therapeutics (CNTX) Earnings Date, Estimates & Call Transcripts $0.74 +0.04 (+5.19%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$0.75 +0.01 (+1.86%) As of 08/14/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Context Therapeutics Earnings Summary Context Therapeutics announced Q2 2025 earnings on August 6, 2025, reporting an EPS of -$0.09, which missed the consensus estimate of -$0.06 by $0.03. With a trailing EPS of -$0.36, Context Therapeutics' earnings are expected to grow next year, from ($0.51) to ($0.31) per share. Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Quarterly Report (10-Q)Powered by Latest Q2 Earnings DateAug. 6EstimatedConsensus EPS (Aug. 6) -$0.06 Actual EPS (Aug. 6) -$0.09 Missed By -$0.03 Get Context Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCNTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Context Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.05-$0.05-$0.05Q2 20252-$0.06-$0.05-$0.06Q3 20252-$0.09-$0.06-$0.08Q4 20252-$0.09-$0.06-$0.08 FY 2025 7 -$0.29 -$0.22 -$0.26 Q1 20261-$0.09-$0.09-$0.09Q2 20261-$0.09-$0.09-$0.09Q3 20261-$0.08-$0.08-$0.08Q4 20261-$0.07-$0.07-$0.07 Context Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025-$0.06-$0.09 -$0.03-$0.09--5/14/2025Q1 2025-$0.05-$0.05--$0.05--3/20/2025Q4 2024-$0.05-$0.04+$0.01---11/6/2024--$0.11-$0.22 -$0.11-$0.22--8/7/2024--$0.08-$0.04+$0.04-$0.04--5/8/2024Q1 2024-$0.38-$0.23+$0.15-$0.23--3/21/2024Q4 2023-$0.35-$0.42 -$0.07-$0.42--11/9/2023Q3 2023-$0.30-$0.37 -$0.07-$0.37-- Context Therapeutics Earnings - Frequently Asked Questions When did Context Therapeutics announce their last quarterly earnings? Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earning data on Wednesday, August 6, 2025. Learn more on CNTX's earnings history. Did Context Therapeutics beat their earnings estimates last quarter? In the previous quarter, Context Therapeutics (NASDAQ:CNTX) missed the analysts' consensus estimate of ($0.06) by $0.03 with a reported earnings per share (EPS) of ($0.09). Learn more on analysts' earnings estimate vs. CNTX's actual earnings. How much profit does Context Therapeutics generate each year? Context Therapeutics (NASDAQ:CNTX) has a recorded net income of -$26.73 million. CNTX has generated -$0.36 earnings per share over the last four quarters. What is Context Therapeutics' EPS forecast for next year? Context Therapeutics' earnings are expected to grow from ($0.51) per share to ($0.31) per share in the next year. More Earnings Resources from MarketBeat Related Companies SGMT Earnings Results NMRA Earnings Results ACB Earnings Results MNPR Earnings Results DBVT Earnings Results DRUG Earnings Results ALLO Earnings Results GALT Earnings Results TKNO Earnings Results ALMS Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Brinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings Beat This page (NASDAQ:CNTX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access